Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
2,210.00
+15.00 (0.68%)
At close: Sep 9, 2026
Kangstem Biotech Revenue
Kangstem Biotech had revenue of 641.99M KRW in the quarter ending June 30, 2026, a decrease of -81.13%. This brings the company's revenue in the last twelve months to 3.03B, down -76.24% year-over-year. In the year 2025, Kangstem Biotech had annual revenue of 3.57B, down -53.88%.
Revenue (ttm)
3.03B
Revenue Growth
-76.24%
P/S Ratio
68.50
Revenue / Employee
31.28M
Employees
97
Market Cap
207.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57B | -4.17B | -53.88% |
| Dec 31, 2024 | 7.75B | -4.96B | -39.03% |
| Dec 31, 2023 | 12.70B | -3.60B | -22.06% |
| Dec 31, 2022 | 16.30B | 3.90B | 31.41% |
| Dec 31, 2021 | 12.40B | 3.27B | 35.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 124.81B |
| ISU Abxis | 51.04B |
| Genome & Company | 24.46B |
| NIBEC | 22.60B |
| Bio Solution | 17.39B |
| S.Biomedics | 16.49B |
| curacle co.,ltd. | 8.24B |
| IntoCell | 3.19B |